Compare Amgen, Inc. (AMGN) vs NetFlix Inc (NFLX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs NetFlix Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while NetFlix Inc trades at $73.75 (market cap $308.95B). The key difference: NetFlix Inc is the larger of the two by market cap, and Amgen, Inc. pays a 2.77% dividend while NetFlix Inc pays none. Which is the better fit depends on your goals.
| AMGN | NFLX | |
|---|---|---|
Market Cap | $196.12B | $308.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $127.42 |
52-Week Low | $271.18 | $70.91 |
Enterprise Value | $241.41B | $311.02B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Netflix (NFLX) trades at $73.37, down 2.78% on the day, reflecting recent bearish momentum amid a mixed technical backdrop. Fundamentally, the company shows strong profitability with a 28.52% net income margin and robust revenue growth, reaching $45.18B in 2025. Analyst consensus remains bullish with a $111.80 price target, though recent news highlights stock weakness despite business expansion in advertising and content.
The outlook for NFLX hinges on scaling its ad-supported tier and live sports initiatives, offering significant upside if execution succeeds. Risks include intense streaming competition and market sentiment shifts. With solid cash flow growth and high institutional confidence, the stock presents a value opportunity for long-term investors despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
